|  Help  |  About  |  Contact Us

Publication : Splenic SUMO1 controls systemic inflammation in experimental sepsis.

First Author  Youssef A Year  2023
Journal  Front Immunol Volume  14
Pages  1200939 PubMed ID  37520526
Mgi Jnum  J:343824 Mgi Id  MGI:7515428
Doi  10.3389/fimmu.2023.1200939 Citation  Youssef A, et al. (2023) Splenic SUMO1 controls systemic inflammation in experimental sepsis. Front Immunol 14:1200939
abstractText  INTRODUCTION: The recent discovery of TAK981(Subasumstat), the first-in-class selective inhibitor of SUMOylation, enables new immune treatments. TAK981 is already in clinical trials to potentiate immunotherapy in metastatic tumors and hematologic malignancies. Cancer patients have more than ten times higher risk of infections, but the effects of TAK981 in sepsis are unknown and previous studies on SUMO in infections are conflicting. METHODS: We used TAK981 in two sepsis models; polymicrobial peritonitis (CLP) and LPS endotoxemia. Splenectomy was done in both models to study the role of spleen. Western blotting of SUMO-conjugated proteins in spleen lysates was done. Global SUMO1 and SUMO3 knockout mice were used to study the specific SUMO regulation of inflammation in LPS endotoxemia. Splenocytes adoptive transfer was done from SUMO knockouts to wild type mice to study the role of spleen SUMOylation in experimental sepsis. RESULTS AND DISCUSSION: Here, we report that inhibition of SUMOylation with TAK981 improved survival in mild polymicrobial peritonitis by enhancing innate immune responses and peritoneal bacterial clearance. Thus, we focused on the effects of TAK981 on the immune responses to bacterial endotoxin, showing that TAK981 enhanced early TNFalpha production but did not affect the resolution of inflammation. Splenectomy decreased serum TNFalpha levels by nearly 60% and TAK981-induced TNFalpha responses. In the spleen, endotoxemia induced a distinct temporal and substrate specificity for SUMO1 and SUMO2/3, and both were inhibited by TAK981. Global genetic depletion of SUMO1, but not SUMO3, enhanced TNFalpha production and metabolic acidosis. The transfer of SUMO1-null, but not wild-type, splenocytes into splenectomized wild-type mice exacerbated TNFalpha production and metabolic acidosis in endotoxemia. CONCLUSION: These results suggest that specific regulation of splenic SUMO1 can modulate immune and metabolic responses to bacterial infection.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

6 Bio Entities

Trail: Publication

0 Expression